Cell Therapy Deramiocel Demonstrates Efficacy in Duchenne Muscular Dystrophy Trial

A Phase 3 clinical trial published in The Lancet indicates that deramiocel cell therapy can slow muscle weakening and heart damage in boys and young men with advanced Duchenne muscular dystrophy. Participants receiving the therapy experienced a significantly slower decline in arm and elbow movement compared to the placebo group. This development offers potential new treatment avenues for the progressive genetic disorder.